Spinal Restoration, Baxter in fibrin sealant partnership:
This article was originally published in Clinica
Executive Summary
Minimally-invasive back pain therapy specialist Spinal Restoration has entered into an exclusive long-term agreement with Baxter Healthcare to develop and further expand the applications of the former's Biostat Biologx fibrin sealant. The deal will see Biostat Biologx combined with Baxter's own fibrin sealant to create the Biostat disc augmentation system, a minimally-invasive product for the treatment of painful degeneration of intervertebral discs. Spinal Restoration (Austin, Texas) said that the partnership will enable it to further its preparation for an investigational device exemption clinical study, scheduled for the first quarter of 2008.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.